Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Sep 11 - Sep 16
ACT-AD Phase 2 Trial Fosgonimeton's Phase 2 ACT-AD trial in Alzheimer's patients fails its primary endpoint
A009402
Discontinue use if signs of hypersensitivity, such as rash or anaphylaxis, occur
Start with a moderate, consistent dose (e.g
Topical Application: For skin injuries, topical preparations have been used in research, typically applied 2 to 3 times per day directly to the affected area
Men with existing medical conditions or those taking medications should consult with healthcare providers before beginning peptide therapy
US$ 22.18
US$ 28.38
US$ 20.70
US$ 21.28
US$ 27.10
US$ 25.65
